Navigation Links
Melanoma of the rectum: A rare entity

Primary anorectal melanoma is a rare and very aggressive disorder. A report published on March 14, 2008, in the World Journal of Gastroenterology addresses such a case. A 41-year-old man presented with a 6-month history of changed defecation and rectal bleeding. A 3-cm polypoid tumor of the lower rectum was found at rectosigmoidoscopy, which proved to be a leiomyosarcoma upon biopsy. Dissemination studies did not show any metastases. He underwent an APR. The histopathology of the specimen showed a melanoma (S-100 stain positive). Two years after the resection, metastases in the abdomen and right lung were found. He died a year and a half later.

In the view of the authors, if there is suspicion of an anorectal sarcoma, one should always perform an S-100 stain following a biopsy. A positive S-100 stain indicates that the tumor is most likely to be a melanoma. Depending on the outcome of the dissemination studies, a surgical resection has to be performed. It has been thought that a sphincter-saving local excision combined with adjuvant locoregional radiotherapy should be preferred in the case of small tumors. The same locoregional control is achieved with less loss of function compared to non-sphincter-saving surgery. Only in the case of large and obstructing tumors is an abdominoperineal resection the treatment of choice.


Contact: Jing Zhu
World Journal of Gastroenterology

Page: 1

Related medicine news :

1. Melanoma Diagnosis Often Delayed for Rural Poor
2. Melanoma drug revs immune cells but cancer cells ignore it
3. Promising drug combination may help those with ocular melanoma that has spread
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
6. New type of drug shows promise in attacking melanoma in an innovative way
7. Genes Unlock New Treatments for Deadly Melanoma
8. Top-Line Data Available from Three Ipilimumab Pivotal Trials in Patients with Advanced Metastatic Melanoma
9. Researchers Hone in on Cancer Stem Cells for Melanoma
10. Melanomas may appear noticeably different than other moles
11. Melanomas Present Unique Appearance
Post Your Comments:
(Date:11/26/2015)... Las Vegas, NV (PRWEB) , ... November 26, 2015 , ... ... holiday shopping strategy. Many customers choose to buy during the Black Friday and ... holiday gifts. Shoppers don’t need to search the Internet high and low to find ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... system for diagnostic imaging in the Waterloo region. Using the Ocean Platform, family ... tests directly from their electronic medical record (EMR) without the need for redundant ...
(Date:11/26/2015)... Ashburn, VA (PRWEB) , ... November 26, 2015 ... ... Planners, an American Express Travel Representative. As a franchise owner, Somu now offers ... range of cruise, destination wedding packages, private cruise sales, as well as, cabin ...
(Date:11/26/2015)... ... , ... The Catalent Applied Drug Delivery Institute today announced ... form selection in early phase drug development. The first of these is to ... the UK’s emerging life sciences companies, corporate partners, and investors, at Milton Park, ...
(Date:11/26/2015)... ... 2015 , ... Jobs in hospital medical laboratories and in the imaging field ... agency Aureus Medical Group . These fields, as well as travel ... for healthcare jobs through the company’s website, , The leading healthcare ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Cell Surface Marker Testing Market: Supplier ... to their offering.  --> ... of the  "2016 Future Horizons and ...
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, a ... treatment outcomes for patients suffering from chronic pain, said ... a Temporary Restraining Order (TRO) enjoining Express Scripts from ... companies. --> --> ... of its legal options. --> ...
(Date:11/25/2015)... Kitov Pharma ceuticals ... biopharmaceutical company focused on the development of therapeutic candidates ... announced the closing of its previously announced underwritten public ... each representing 20 ordinary shares of the Company, and ... and warrants were issued in a fixed combination of ...
Breaking Medicine Technology: